These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12492078)

  • 41. Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.
    Rice C; Wilantewicz H
    AIDS Read; 2006 Sep; 16(9):470-4, 490-1. PubMed ID: 17024766
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel therapies based on mechanisms of HIV-1 cell entry.
    Kilby JM; Eron JJ
    N Engl J Med; 2003 May; 348(22):2228-38. PubMed ID: 12773651
    [No Abstract]   [Full Text] [Related]  

  • 43. [Combined treatment with fusion inhibitor. HIV-1 viruses under control longer].
    MMW Fortschr Med; 2004 Apr; 146(15):68. PubMed ID: 15373030
    [No Abstract]   [Full Text] [Related]  

  • 44. Alternative administration options for Fuzeon.
    AIDS Patient Care STDS; 2007 Nov; 21(11):891. PubMed ID: 18338434
    [No Abstract]   [Full Text] [Related]  

  • 45. Anti-HIV agents. T-20 shows its potency.
    TreatmentUpdate; 2002 Aug; 14(6):5-6. PubMed ID: 12238452
    [No Abstract]   [Full Text] [Related]  

  • 46. Anti-HIV agents. Access denied--keeping HIV out with entry inhibitors.
    TreatmentUpdate; 2006; 18(4):4. PubMed ID: 17205653
    [No Abstract]   [Full Text] [Related]  

  • 47. [Enfuvirtide. Two injections per day for HIV].
    Taéron C
    Rev Infirm; 2004 Oct; (104):35-6. PubMed ID: 15581312
    [No Abstract]   [Full Text] [Related]  

  • 48. Formal approval for Fuzeon.
    AIDS Patient Care STDS; 2004 Dec; 18(12):736. PubMed ID: 15659885
    [No Abstract]   [Full Text] [Related]  

  • 49. Fusion inhibitor trials halted.
    AIDS Patient Care STDS; 2004 Mar; 18(3):182-3. PubMed ID: 15112641
    [No Abstract]   [Full Text] [Related]  

  • 50. [Enfuvirtida (Fuzeon). Laboratory: Roche & Trimeris].
    Moreno Alvarez PJ
    Farm Hosp; 2003; 27(4):271-2. PubMed ID: 12966457
    [No Abstract]   [Full Text] [Related]  

  • 51. [Entry inhibitors. Ring-free for a new principle of action].
    Rümmelein N; Jäger H
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():16-20. PubMed ID: 15011578
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fusion inhibitors: T-20 and T-1249.
    TreatmentUpdate; 2001; 12(12):2-3. PubMed ID: 11570088
    [No Abstract]   [Full Text] [Related]  

  • 53. Enfuvirtide and cutaneous injection-site reactions.
    Mirza RA; Turiansky GW
    J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Misleading efficacy claims for Fuzeon.
    AIDS Patient Care STDS; 2005 Sep; 19(9):614. PubMed ID: 16247841
    [No Abstract]   [Full Text] [Related]  

  • 55. [New treatments against AIDS: fusion inhibitors].
    Holzgrabe U
    Pharm Unserer Zeit; 2004; 33(1):6. PubMed ID: 14968706
    [No Abstract]   [Full Text] [Related]  

  • 56. T-20 being called "miraculous".
    AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581
    [No Abstract]   [Full Text] [Related]  

  • 57. Katy, bar the door! HIV entry inhibitors.
    Martinez LJ
    Res Initiat Treat Action; 2000 Jun; 6(2):6-12. PubMed ID: 11707878
    [No Abstract]   [Full Text] [Related]  

  • 58. A delayed hypersensitivity reaction to enfuvirtide after rechallenge.
    Emerson CR; Post JJ; Workman C
    Int J STD AIDS; 2009 Apr; 20(4):288-9. PubMed ID: 19304981
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [HIV-1 fusion inhibitor improves treatment in HIV-1-resistant patients].
    Blasko M
    Dtsch Med Wochenschr; 2003 May; 128(19):1032. PubMed ID: 12774800
    [No Abstract]   [Full Text] [Related]  

  • 60. [Editorial: Interview with Father Hervé Gallais, Conception Hospital, Marseille].
    Med Mal Infect; 2004 Sep; 34 Spec No 1():1-2. PubMed ID: 15742548
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.